Search

everythinglearnresearchcommunity

for

Search:↓

Stemoxydine is discussed as a hair loss treatment with no reported side effects. The conversation explores its effectiveness and safety.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

A 23-year-old started using 0.5mg Dutasteride and 2.5mg Minoxidil daily for hair loss and is considering adding RU58841 or GHK-cu. Users suggest waiting a few months before adding anything and mention Koshine's kx-826 as a potentially better alternative to RU58841.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Users are asked to share their experiences with Pyri/Koshine.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

A user inquired about purchasing KX-826 for hair loss if approved in China. Another user provided links to purchase it without waiting for U.S. approval.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

A user experienced increased pimples and cysts after two years on dutasteride, possibly due to hormonal changes. Suggestions included seeing an endocrinologist, using supplements like boron and DIM, adjusting diet, and reducing body fat to manage side effects.

The conversation humorously discusses hair loss treatments, mentioning a regime of 1mg oral finasteride, 5% topical finasteride, and 1mg kryptonite. It also references the use of minoxidil for hair regrowth.

KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A user is waiting for pyrilutamide delivery and is seeking reviews, especially regarding side effects. No reviews have been mentioned in the conversation.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

Treatments for hair loss (Dutasteride, Finasteride and Minoxidil) and the potential benefits of adding Stemoxydine to the treatment.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation humorously discusses hair loss treatments, specifically finasteride, minoxidil, and dutasteride, and their prevalence in Japan. It highlights the common use of these treatments among Japanese salarymen and the ease of obtaining them online or through clinics.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

A user discusses their rapidly receding hairline and a prescribed topical solution containing 7% Minoxidil, 0.1% Finasteride, and 3% biotinoyl tripeptide. The solution is a custom compound from their dermatologist, costing $50 for a one-month supply.

A user's 8 month progress with treatments including dutasteride, minoxidil, RU58841, derma roller, ketoconazole shampoo and stemoxydine to combat hair loss. Others have shared their own experiences and regrowth results with similar treatments.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The user is sharing their experience with using 0.5mg dutasteride, 2.5mg oral minoxidil, and hair dye for 45 days. Another user encourages them to continue as it is still too early to see significant improvement.